SI9300678A - Atovaquone/proquanyl combinations and their uses - Google Patents
Atovaquone/proquanyl combinations and their uses Download PDFInfo
- Publication number
- SI9300678A SI9300678A SI9300678A SI9300678A SI9300678A SI 9300678 A SI9300678 A SI 9300678A SI 9300678 A SI9300678 A SI 9300678A SI 9300678 A SI9300678 A SI 9300678A SI 9300678 A SI9300678 A SI 9300678A
- Authority
- SI
- Slovenia
- Prior art keywords
- atovaquone
- particles
- pharmaceutical composition
- microfluidized
- mixture
- Prior art date
Links
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 title claims abstract description 38
- 229960003159 atovaquone Drugs 0.000 title claims abstract description 38
- 239000002245 particle Substances 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000000375 suspending agent Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 241000233872 Pneumocystis carinii Species 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000036281 parasite infection Effects 0.000 claims description 2
- 244000000040 protozoan parasite Species 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003993 interaction Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- -1 2-substituted-3-hydroxy-1,4-naphthoquinones Chemical class 0.000 description 2
- BSJMWHQBCZFXBR-UHFFFAOYSA-N 3-[4-(p-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthoquinone Chemical compound O=C1C(=O)C2=CC=CC=C2C(O)=C1C(CC1)CCC1C1=CC=C(Cl)C=C1 BSJMWHQBCZFXBR-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 241000223931 Eimeria acervulina Species 0.000 description 1
- 241000223932 Eimeria tenella Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000223777 Theileria Species 0.000 description 1
- 241000223778 Theileria annulata Species 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fertilizers (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929226905A GB9226905D0 (en) | 1992-12-24 | 1992-12-24 | Pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI9300678A true SI9300678A (en) | 1994-09-30 |
Family
ID=10727175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9300678A SI9300678A (en) | 1992-12-24 | 1993-12-23 | Atovaquone/proquanyl combinations and their uses |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US6018080A (fr) |
| EP (1) | EP0675711B1 (fr) |
| JP (1) | JP3461353B2 (fr) |
| KR (1) | KR0175193B1 (fr) |
| CN (1) | CN1076194C (fr) |
| AT (1) | ATE169215T1 (fr) |
| AU (2) | AU675102B2 (fr) |
| BG (1) | BG61932B1 (fr) |
| BR (1) | BR9307719A (fr) |
| CA (1) | CA2152615C (fr) |
| CZ (1) | CZ289701B6 (fr) |
| DE (1) | DE69320208T2 (fr) |
| DK (1) | DK0675711T3 (fr) |
| ES (1) | ES2122223T3 (fr) |
| FI (1) | FI114007B (fr) |
| GB (1) | GB9226905D0 (fr) |
| GE (1) | GEP19991515B (fr) |
| HK (1) | HK1004086A1 (fr) |
| HR (1) | HRP931516B1 (fr) |
| HU (1) | HU220215B (fr) |
| IL (1) | IL108154A (fr) |
| MY (1) | MY109990A (fr) |
| NO (1) | NO316745B1 (fr) |
| NZ (1) | NZ258995A (fr) |
| PL (1) | PL175374B1 (fr) |
| RO (1) | RO119686B1 (fr) |
| RU (1) | RU2127585C1 (fr) |
| SA (1) | SA94140644B1 (fr) |
| SG (1) | SG43901A1 (fr) |
| SI (1) | SI9300678A (fr) |
| SK (1) | SK281924B6 (fr) |
| TW (2) | TW514531B (fr) |
| UA (1) | UA39879C2 (fr) |
| WO (1) | WO1994014426A1 (fr) |
| YU (1) | YU48919B (fr) |
| ZA (1) | ZA939673B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224739D0 (en) * | 1992-11-26 | 1993-01-13 | Wellcome Found | Medicaments |
| GB9226905D0 (en) * | 1992-12-24 | 1993-02-17 | Wellcome Found | Pharmaceutical preparation |
| AU3705695A (en) * | 1994-10-26 | 1996-05-23 | Wellcome Foundation Limited, The | Pharmaceutical composition comprising atovaquone |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| GB9424013D0 (en) * | 1994-11-29 | 1995-01-18 | Wellcome Found | Medicaments |
| AU753278B2 (en) * | 1998-02-25 | 2002-10-10 | Abbott Laboratories | Butorphanol sustained release formulations |
| US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6706744B2 (en) | 2000-11-17 | 2004-03-16 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| AU2002223500A1 (en) | 2000-11-17 | 2002-05-27 | Novo-Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6821960B2 (en) | 2000-11-17 | 2004-11-23 | Noyo Nordisk Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| US7183518B2 (en) * | 2004-09-24 | 2007-02-27 | Michael Near | System of food storage preparation and delivery in finished cooked state |
| DE102005011786A1 (de) * | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
| JP5080445B2 (ja) * | 2005-04-13 | 2012-11-21 | アボット ゲーエムベーハー ウント コー． カーゲー | 超微粒子懸濁液及び超微粒子を穏やかに製造する方法並びにその使用 |
| US20080241254A1 (en) * | 2007-01-02 | 2008-10-02 | Suryakant Navale | Pharmaceutical composition comprising atovaquone particles |
| DE102007001473A1 (de) | 2007-01-08 | 2008-07-10 | Andreas Lemke | Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck |
| WO2009007991A2 (fr) * | 2007-04-19 | 2009-01-15 | Ipca Laboratories Limited | Nouveau procédé de préparation d'atovaquone et ses nouveaux intermédiaires |
| US20110206770A1 (en) * | 2008-07-25 | 2011-08-25 | Alphapharm Pty. Ltd. | Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns |
| US20100099776A1 (en) * | 2008-10-20 | 2010-04-22 | Ranbaxy Laboratories Limited | Oily suspension of atovaquone |
| WO2011021230A2 (fr) | 2009-08-20 | 2011-02-24 | Ipca Laboratories Limited | Nouveau complexe pour le traitement et/ou la prophylaxie d'infections parasitaires |
| MX337893B (es) * | 2009-11-10 | 2016-03-28 | Celgene Corp | Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion. |
| WO2011151418A2 (fr) | 2010-06-02 | 2011-12-08 | Abbott Gmbh & Co. Kg | Formulation de nanosuspension comprenant une phase hydrophobe de polydiméthylsiloxane |
| EP2934484A1 (fr) | 2012-12-19 | 2015-10-28 | Kashiv Pharma, LLC | Nanoparticules stabilisées super saturées pour des médicaments médiocrement solubles |
| WO2015071841A1 (fr) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci |
| EP3471697A1 (fr) * | 2016-06-16 | 2019-04-24 | The University of Liverpool | Composition chimique |
| US20220265566A1 (en) * | 2018-10-18 | 2022-08-25 | Tulex Pharmaceuticals Inc. | Atovaquone nanoparticulate compositions |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2533648A (en) * | 1949-03-05 | 1950-12-12 | Joseph H Warburg | Circular saw making |
| NL6411993A (fr) * | 1963-10-18 | 1965-04-20 | ||
| US3347830A (en) * | 1964-07-30 | 1967-10-17 | Grace W R & Co | Process of polymerizing formaldehyde |
| GB1141735A (en) * | 1966-11-23 | 1969-01-29 | Pfizer & Co C | Pharmaceutical anti-tumor composition |
| US3655699A (en) * | 1970-03-02 | 1972-04-11 | Pfizer | Analogues of lapachol as antitumor agents |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| DE2601458A1 (de) * | 1975-01-20 | 1976-07-22 | Ciba Geigy Ag | Loesliche, von phenylindandiaminen abgeleitete polyamide |
| EG14152A (en) * | 1977-11-22 | 1983-12-31 | Wellcome Found | Antitheilerial naphtoquinone derivatives |
| US4485117A (en) | 1981-10-16 | 1984-11-27 | Hudson Alan T | Antiprotozoal compounds |
| US4485116A (en) * | 1981-10-16 | 1984-11-27 | Hudson Alan T | Antiprotozoal compounds |
| DE3141691A1 (de) * | 1981-10-21 | 1983-05-19 | Hoechst Ag, 6230 Frankfurt | Plasmid pac 1, verfahren zu seiner gewinnung und seine verwendung |
| US5053432A (en) * | 1983-04-14 | 1991-10-01 | Burroughs Wellcome Co. | Naphthoquinone derivatives |
| GB8310141D0 (en) * | 1983-04-14 | 1983-05-18 | Wellcome Found | Naphthoquinone derivatives |
| US5175319A (en) | 1983-04-14 | 1992-12-29 | Burroughs Wellcome Co. | Naphthoquinone derivatives |
| GB8310140D0 (en) * | 1983-04-14 | 1983-05-18 | Wellcome Found | Antiprotozoal agents |
| US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| PL276385A1 (en) * | 1987-01-30 | 1989-07-24 | Exxon Chemical Patents Inc | Method for polymerization of olefines,diolefins and acetylene unsaturated compounds |
| IL85097A (en) * | 1987-01-30 | 1992-02-16 | Exxon Chemical Patents Inc | Catalysts based on derivatives of a bis(cyclopentadienyl)group ivb metal compound,their preparation and their use in polymerization processes |
| US4783389A (en) * | 1987-03-27 | 1988-11-08 | E. I. Du Pont De Nemours And Company | Process for preparation of liquid electrostatic developers |
| US5155080A (en) * | 1988-07-15 | 1992-10-13 | Fina Technology, Inc. | Process and catalyst for producing syndiotactic polyolefins |
| US5225500A (en) * | 1988-07-15 | 1993-07-06 | Fina Technology, Inc. | Process and catalyst for producing syndiotactic polyolefins |
| GB8819477D0 (en) * | 1988-08-16 | 1988-09-21 | Wellcome Found | Medicaments |
| US5206268A (en) * | 1988-08-16 | 1993-04-27 | Burroughs Wellcome Co. | Medicaments |
| US5225184A (en) * | 1988-08-16 | 1993-07-06 | Burroughs Wellcome Co. | Medicaments |
| DE68928964T2 (de) * | 1988-08-16 | 1999-07-29 | Wellcome Found | Neue Naphthochinone und ihre Anwendung als Arzneimittel |
| KR930002411B1 (ko) * | 1988-09-14 | 1993-03-30 | 미쓰이세끼유 가가꾸고오교오 가부시끼가이샤 | 벤젠불용성 유기알루미늄 옥시화합물 및 그 제조방법 |
| GB8921516D0 (en) * | 1989-09-22 | 1989-11-08 | Wellcome Found | Medicaments |
| CA2027145C (fr) * | 1989-10-10 | 2002-12-10 | Michael J. Elder | Catalyseurs a base de metallocene, d'acides de lewis et d'alkylaluminium |
| GB8923254D0 (en) * | 1989-10-16 | 1989-12-06 | Wellcome Found | Medicaments |
| CA2027122C (fr) * | 1989-10-30 | 2002-12-10 | John A. Ewen | Preparation de systemes catalytiques a base de metallocene et d'alkylaluminium pour la polymerisation dirigee d'olefines |
| US5387568A (en) * | 1989-10-30 | 1995-02-07 | Fina Technology, Inc. | Preparation of metallocene catalysts for polymerization of olefins |
| DE3942363A1 (de) * | 1989-12-21 | 1991-06-27 | Hoechst Ag | Verfahren zur herstellung einer polypropylen-formmasse |
| JP2545006B2 (ja) * | 1990-07-03 | 1996-10-16 | ザ ダウ ケミカル カンパニー | 付加重合触媒 |
| JP3076619B2 (ja) | 1991-05-14 | 2000-08-14 | 三井化学株式会社 | ブロック共重合体の製造方法 |
| GB9226905D0 (en) * | 1992-12-24 | 1993-02-17 | Wellcome Found | Pharmaceutical preparation |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5766522A (en) * | 1996-07-19 | 1998-06-16 | Morton International, Inc. | Continuous processing of powder coating compositions |
| US5976578A (en) * | 1996-10-10 | 1999-11-02 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
| US5914135A (en) * | 1997-04-16 | 1999-06-22 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
-
1992
- 1992-12-24 GB GB929226905A patent/GB9226905D0/en active Pending
-
1993
- 1993-12-20 GE GEAP19931692A patent/GEP19991515B/en unknown
- 1993-12-22 YU YU80893A patent/YU48919B/sh unknown
- 1993-12-23 JP JP51496894A patent/JP3461353B2/ja not_active Expired - Lifetime
- 1993-12-23 ZA ZA939673A patent/ZA939673B/xx unknown
- 1993-12-23 DK DK94902952T patent/DK0675711T3/da active
- 1993-12-23 RU RU95122758A patent/RU2127585C1/ru active
- 1993-12-23 TW TW088101847A patent/TW514531B/zh not_active IP Right Cessation
- 1993-12-23 SI SI9300678A patent/SI9300678A/sl unknown
- 1993-12-23 EP EP94902952A patent/EP0675711B1/fr not_active Expired - Lifetime
- 1993-12-23 CA CA002152615A patent/CA2152615C/fr not_active Expired - Lifetime
- 1993-12-23 UA UA95062971A patent/UA39879C2/uk unknown
- 1993-12-23 PL PL93309629A patent/PL175374B1/pl unknown
- 1993-12-23 HU HU9501812A patent/HU220215B/hu unknown
- 1993-12-23 AT AT94902952T patent/ATE169215T1/de active
- 1993-12-23 RO RO95-01191A patent/RO119686B1/ro unknown
- 1993-12-23 MY MYPI93002823A patent/MY109990A/en unknown
- 1993-12-23 BR BR9307719-0A patent/BR9307719A/pt not_active Application Discontinuation
- 1993-12-23 AU AU57105/94A patent/AU675102B2/en not_active Expired
- 1993-12-23 DE DE69320208T patent/DE69320208T2/de not_active Expired - Lifetime
- 1993-12-23 WO PCT/GB1993/002646 patent/WO1994014426A1/fr active IP Right Grant
- 1993-12-23 SK SK828-95A patent/SK281924B6/sk not_active IP Right Cessation
- 1993-12-23 NZ NZ258995A patent/NZ258995A/en not_active IP Right Cessation
- 1993-12-23 CN CN93121376A patent/CN1076194C/zh not_active Expired - Fee Related
- 1993-12-23 SG SG1996004546A patent/SG43901A1/en unknown
- 1993-12-23 HR HR9226905.9A patent/HRP931516B1/xx not_active IP Right Cessation
- 1993-12-23 TW TW082110927A patent/TW443935B/zh not_active IP Right Cessation
- 1993-12-23 ES ES94902952T patent/ES2122223T3/es not_active Expired - Lifetime
- 1993-12-23 CZ CZ19951451A patent/CZ289701B6/cs not_active IP Right Cessation
- 1993-12-23 KR KR1019950702217A patent/KR0175193B1/ko not_active IP Right Cessation
- 1993-12-23 IL IL10815493A patent/IL108154A/xx not_active IP Right Cessation
-
1994
- 1994-04-03 SA SA94140644A patent/SA94140644B1/ar unknown
-
1995
- 1995-06-15 BG BG99723A patent/BG61932B1/bg unknown
- 1995-06-22 FI FI953139A patent/FI114007B/fi not_active IP Right Cessation
- 1995-06-22 NO NO19952522A patent/NO316745B1/no not_active IP Right Cessation
-
1997
- 1997-03-14 AU AU16279/97A patent/AU696662B2/en not_active Ceased
- 1997-11-19 US US08/974,248 patent/US6018080A/en not_active Expired - Lifetime
-
1998
- 1998-04-20 HK HK98103299A patent/HK1004086A1/xx not_active IP Right Cessation
-
1999
- 1999-10-04 US US09/411,381 patent/US6649659B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9300678A (en) | Atovaquone/proquanyl combinations and their uses | |
| AU2007240317B2 (en) | Stable emulsion formulations | |
| RU2642234C2 (ru) | Композиции антагонистов нейрокинина-1 для внутривенного введения | |
| RU2462250C2 (ru) | Новая композиция, основанная на оксиме холест-4-ен-3-она | |
| EP1249230B1 (fr) | Microémulsions et préconcentrés en microémulsion comprenant de la coenzyme Q10 | |
| DE60225154T2 (de) | Neues selbstemulgierendes arzneimittelfreisetzungssystem | |
| US20200215027A1 (en) | Dihydromyricetin nanoemulsion formulations and methods for forming them | |
| CN108553417B (zh) | 一种蛇床子素自乳化释药系统及其制备方法与用途 | |
| Yin et al. | Development and in vitro and in vivo evaluations of a microemulsion formulation for the oral delivery of oxaprozin | |
| Kleynhans et al. | A toxicity profile of the Pheroid® technology in rodents | |
| Rajni et al. | Advancement in Novel Drug Delivery System: Niosomes. | |
| Jigar et al. | Development of stable multiple emulsion of atorvastatin | |
| Sadat et al. | Effect of cellulosic and polymethacrylic polymers on drug content, particle morphology, and carbamazepine release profiles from sustained release ethyl cellulose microspheres | |
| Mogahed et al. | Potential efficacy of curcumin and curcumin nanoemulsion against experimental cyclosporiasis | |
| CN116440080A (zh) | 一种红花黄色素纳米柔性脂质体及其制备方法 | |
| CN110548004A (zh) | 一种稳定的丁苯酞大容量注射液及其制备方法 | |
| KR20130071951A (ko) | 다중 에멀션에 의한 수용성 활성물질과 지용성 활성물질이 함께 함유된 마이크로스피어, 이의 제조방법 및 이를 함유하는 화장료 조성물 | |
| OBITTE et al. | FORMULATION AND IN VITRO EVALUATION OF PHOSPHOLIPON® 90 H-BASED MICROPARTICLES FOR ORAL DELIVERY OF ARTEMETHER-LUMEFANTRINE CHUKWUEMEKA CHRISTIAN MBAH*, SYLVESTER OGBONNA, ANDREW CHEKWUBE EZEGBE, OGOCHUKWU NGOZIKA CHIDINMA UMEH, JOSEPHAT IKECHUKWU OGBONNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date |